98%
921
2 minutes
20
Purpose: To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG.
Materials And Methods: We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: BCH (development dataset, n=214 [60 (28%) BRAF fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and Child Brain Tumor Network (CBTN) (external validation, n=112 [60 (53%) BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs. fusion vs. wildtype) via a two-stage process: 1) 3D tumor segmentation and extraction of axial tumor images, and 2) slice-wise, deep learning-based classification of mutational status. We investigated knowledge-transfer and self-supervised approaches to prevent model overfitting with a primary endpoint of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, we developed a novel metric, COMDist, that quantifies the accuracy of model attention around the tumor.
Results: A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest macro-average AUC (0.82 [95% CI: 0.70-0.90]) and accuracy (77%) on internal validation, with an AUC improvement of +17.7% and a COMDist improvement of +6.4% versus training from scratch. On external validation, the TransferX model yielded AUC (0.73 [95% CI 0.68-0.88]) and accuracy (75%).
Conclusion: Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pLGG mutational status prediction in a limited data scenario.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441478 | PMC |
http://dx.doi.org/10.1101/2023.08.04.23293673 | DOI Listing |
J Cancer Res Clin Oncol
September 2025
Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Purpose: Next-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.
Methods: We conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024.
Biochimie
September 2025
Department of Oncology, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China. Electronic address:
The nuclear factor of activated T cells 3 (NFATc3) plays a significant role in various cancer-related processes, but its interactions with transcriptional modulators, particularly Promyelocytic Leukemia protein (PML), remain poorly understood. PML, a nuclear scaffold protein, is involved in tumor suppression and transcriptional regulation. This study investigates the interaction between NFATc3 and PML, focusing on the role of SUMOylation and its impact on downstream target genes.
View Article and Find Full Text PDFESMO Open
September 2025
Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, USA.
Background: Alterations in DNA damage repair (DDR) pathway genes can be exploited by cytotoxic chemotherapy regimens that induce DNA damage. Platinum chemotherapy has been shown to be particularly effective in DDR-mutated populations. However, the clinical impact of DDR mutations in metastatic colorectal cancer is still unknown.
View Article and Find Full Text PDFCancer Genet
September 2025
Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of Korea. Electronic address:
Background: Homologous recombination deficiency (HRD)-related genetic mutations in ovarian high-grade serous carcinoma (HGSC) are known to be ethnic specific. Here, we assessed the diagnostic performance of HRD and its clinical implication in Korean HGSC patients using the SOPHiA DDM HRD Solution.
Methods: Sixty-three ovarian cancer (OC) patients were enrolled, including 53 with HGSC and 10 with other subtypes.
Pathol Res Pract
September 2025
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Our research aims to ascertain the value of precursor and outgrowth lepidic in aiding the confirmation of multiple lung adenocarcinomas as separate primary lung cancers (SPLC). A total of 151 patients with metachronous multiple invasive adenocarcinomas were included in this study. Driver mutation tests(at least five genes: EGFR, ALK, KRAS, BRAF, and ROS1) were conducted on 302 tumors collected from 151 patients.
View Article and Find Full Text PDF